Disitamab Vedotin Shows Promising Results in Advanced Urothelial Carcinoma Treatment at 2024 ESMO Congress
On 15th September 2024, the 2024 ESMO Congress in Barcelona, Spain, showcased the latest data on Disitamab Vedotin, revealing its promising efficacy and manageable safety profiles when used in combination with a PD-1 inhibitor as a first-line treatment for patients with advanced urothelial carcinoma.
- Median OS of 33.1 Months: A phase Ib/II clinical trial led by Professor Jun Guo from Beijing Cancer Hospital reported a median overall survival (OS) of 33.1 months for patients treated with Disitamab Vedotin plus Toripalimab, significantly longer than the 13 months observed with first-line platinum-containing chemotherapy.
- Study Details: The study enrolled 41 subjects with a median age of 66, showing a confirmed objective response rate (cORR) of 75.0% overall and 88.9% in subjects with HER2 IHC 2+. The median follow-up period was 33.2 months, with a median progression-free survival (mPFS) of 9.3 months.
- Global Multicenter Clinical Study: Dr. M. Galsky presented findings from the RC48G001 Cohort C study, highlighting a cORR of 75% overall and up to 78.6% among HER2-low subjects, with a manageable safety profile.
Urothelial Carcinoma Treatment Landscape: Urothelial carcinoma, accounting for over 90% of bladder cancer cases, is the second most common malignancy of the urinary system. The combination of ADC (Antibody Drug Conjugate) with immunotherapy is reshaping the treatment landscape, offering new hope for patients with HER2-expressing locally advanced or metastatic urothelial carcinoma.
Future Prospects: The global multicenter phase 3 study (DV-001) of Disitamab Vedotin combined with Pembrolizumab versus chemotherapy is proceeding smoothly, with data expected in the first half of 2025. This combination therapy represents a significant advancement in the treatment of advanced urothelial carcinoma, potentially offering a new standard of care.